EBS: Emergent BioSolutions Growth-Adjusted Market Cap to Net Income

The undervalued "rockets" filter by PEG demonstrates the potential of Emergent BioSolutions (EBS), where the value of 7.07 reflects this status. Growth is driven by Narcan sales and contracts with the Pentagon. The business is currently undergoing a recovery phase following reorganization, supported by stable government orders. Its status as a key US partner in biodefense confirms high confidence in the developer of national security tools.

EBS: Emergent BioSolutions Inc. Price/Earnings to Growth Multiple 07/04/2022 - 11/10/2026

Analytical breakdowns for Emergent BioSolutions (EBS)

- current price and projected stock value:

Price Chart Emergent BioSolutions Inc|EBS - Analyst Consensus Forecast

- market capitalization information:

Market Capitalization Emergent Corp|EBS - Total Company Value

- company book value details:

Accounting Value of a Share Emergent BioSolutions|EBS - Company Net Assets|Market Capitalization to Book Value Ratio emergentbiosolutions.com|EBS - Aggregate Company Assets

- issuer credit burden and liquidity indicators:

- earnings and valuation multiples information:

EBS - Net Profit|Projected Net Profit Emergent BioSolutions|EBS - P/E Multiple|Projected Price to Earnings Ratio Emergent Bio|EBS - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Emergent Corp|EBS - Operating profit before deduction of amortization|Earnings per share for the last four quarters Emergent BioSolutions|EBS - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months emergentbiosolutions.com|EBS - Earnings growth in current year|Net earnings per share growth forecast for next year Emergent BioSolutions

Fundamental company analysis:EBS (Emergent BioSolutions Inc)

Emergent BioSolutions investments in environmental safety and wastewater treatment require significant capital, which directly impacts net income dynamics. This growth stock attractiveness indicator compares the company's market value to its revenue growth rate, where a value below one signals that the business is undervalued relative to its development pace and possesses a high capital margin of safety.

Competing companies